Asymptomatic Myeloma Prognosis

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
risk group
—امتیاز
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • ——
  • ——
  • ——
Direct Clinical Answer

The Asymptomatic Myeloma Prognosis calculates predicting risk of progression of asymptomatic (smoldering) multiple myeloma to active myeloma or amyloidosis. Key inputs include bone marrow plasmacytosis. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Predicts risk of progression of asymptomatic (smoldering) multiple myeloma to active myeloma or amyloidosis

Clinical Indication

The Asymptomatic Myeloma Prognosis is indicated for bedside clinical practice to support Predicts risk of progression of asymptomatic (smoldering) multiple myeloma to active myeloma or amyloidosis. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.

Limitations & Contraindications

Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.

Clinical Pearls & Action Plan

Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival.

Formula & Variables:

Risk stratification based on bone marrow plasmacytosis percentage and serum monoclonal protein level: Low Risk (both <10% and <3 g/dL), Intermediate Risk (one factor present), High Risk (both ≥10% and ≥3 g/dL)

Input Parameters

NameTypeRequiredDescription
bone_marrow_plasmacytosisstringYesAverage percentage from bone marrow aspirate and core biopsy(%)
serum_monoclonal_proteinstringYesSerum monoclonal protein level on serum protein electrophoresis(g/dL)

Score Interpretation & Guidance

RangeStageDescription
——Both bone marrow plasmacytosis <10% and serum M-protein <3 g/dL
——Either bone marrow plasmacytosis ≥10% OR serum M-protein ≥3 g/dL (but not both)
——Both bone marrow plasmacytosis ≥10% AND serum M-protein ≥3 g/dL

Evidence-Based References (EBM)

  • Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582-90.
  • Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood. 2015;125(20):3069-75.
  • Mateos MV, Kumar S, Dimopoulos MA, González-Calle V, Kastritis E, Hajek R, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10(10):102.

Related calculators